Survival effect of probiotics in a rat model of colorectal cancer treated with capecitabine

Table 1 Clinicopathological characteristics of animals per group, n (%)

	Control (n = 5)	Control-P (n = 5)	DMH (n = 10)	DMH-C (n = 9)	DMH-P (n = 10)	DMH-C-P (n = 9)
Clinical manifestations
Diarrhea	-	-	3 (30)	2 (22)	1 (10)	-
Constipation	-	-	3 (30)	-	3 (30)	-
Blood stool	-	-	2 (20)	-	4 (40)	-
No manifestations	-	-	2 (20)	7 (78)	2 (20)	9 (100)
Tumor location
Left colon	-	-	7 (70)	3 (33)	5 (63)	2 (22)
Right colon	-	-	1 (10)	1 (11)	2 (25)	2 (22)
Rectum	-	-	2 (20)	-	1 (12)	-
Histological type
Adenocarcinoma	-	-	5 (50)	-	6 (75)	-
Mucinous	-	-	2 (20)	4 (44)	2 (25)	4 (44)
Mixed	-	-	2 (20)	-	-	-
SRCC	-	-	1 (10)	-	-	-
Average tumor size/animal	-	-	2.5	1.0	2.1	1.0
Tumoral burden (cm2)	-	-	4.8	1.81	3.9	1.25
Number of nodes involved in the total number of animals	-	-	4	2	4	-

SRCC: Signet ring cell carcinoma; DMH: 1,2-Dimethylhidrazine dihydrochloride; P: Probiotics; C: Capecitabine.

Table 2 Average body weight for male Wistar Lewis rats in different times of study

Groups	At beginning (g)	At 90 d (g)	At the end of life (g)
Control	329.8 ± 14.41	459.6 ± 15.6	563.0 ± 40.5
Control-P	280.2 ± 11.3	459.6 ± 14.7	619.3 ± 42.0
DMH	361.0 ± 17.6	451.2 ± 22.5	592.8 ± 52.2
DMH-P	361.0 ± 17.6	473.7 ± 23.7	592.8 ± 52.2
DMH-C	299.0 ± 15.7	412.4 ± 17.1	493.0 ± 67.0
DMH-P-C	292.1 ± 34.6	412.7 ± 26.1	559.8 ± 91.9

¹These results are expressed as means ± SD of the body weight.

DMH: 1,2-Dimethylhidrazine dihydrochloride; P: Probiotics; C: Capecitabine.

Table 3 Cause of animal deaths, n (%)

	Control (n = 5)	Control-P (n = 5)	DMH (n = 10)	DMH-C (n = 9)	DMH-P (n = 10)	DMH-C-P (n = 9)
Tumor1	-	-	10 (100)	4 (44.5)	10 (100.0)	4 (44.5)
Lung disease	-	-	-	2 (22.2)	-	-
Underweight	-	-	-	1 (11.1)	-	1 (11.0)
ND	-	-	-	2 (22.2)	-	4 (44.5)
Old age	5 (100)	5 (100)	-	-	-	-

¹Tumoral cause of death: Intestinal obstruction or perforation.

ND: Not determinate; DMH: 1,2-Dimethylhidrazine dihydrochloride; P: Probiotics; C: Capecitabine.